Fine, Kaplan And Black, R.P.C. 宣佈,若您於 2009 年 5 月 1 日至 2019 年 12 月 31 日期間曾在美國支付或償付若干處方仿製藥費用,現可提交集體訴訟和解申索表格
AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

AUDIBLE

Listen free for 30 days with Audible

Thousands of audiobooks and originals — cancel anytime.

Start your free trial

As an affiliate, we earn on qualifying purchases.

Fine, Kaplan and Black, R.P.C., announced a class action settlement for individuals who paid prescription drug costs in the US between May 2009 and December 2019. Eligible claimants can now submit claims to seek reimbursement.

Fine, Kaplan and Black, R.P.C. has announced a class action settlement allowing individuals who paid for prescription drugs in the United States between May 1, 2009, and December 31, 2019 to submit claims for reimbursement. The law firm stated that eligible claimants can now file their claims as part of this settlement, which addresses potential overcharges or improper payments related to prescription medications during that period.

The law firm, representing a group of plaintiffs, confirmed that individuals who paid for prescription drugs in the US during the specified period are eligible to participate in the settlement. The settlement was announced via a press release on PR Newswire and pertains to payments made for certain prescription medications, including generic and brand-name drugs, during the ten-year span.

Claimants are instructed to submit their claims through an official claims process now open, with deadlines and specific eligibility criteria detailed on the settlement website. The firm emphasized that this is a collective effort to address alleged overpayments and ensure reimbursement for those affected.

Legal representatives clarified that this settlement does not imply guilt or liability on the part of any pharmaceutical companies but offers an opportunity for affected individuals to recover costs they may have overpaid.

At a glance
announcementWhen: announced March 2024
The developmentFine, Kaplan and Black, R.P.C., announced a class action settlement for US residents who paid prescription drug costs from 2009 to 2019.
Crypto market snapshot
Fear & Greed Index
26/100 — Fear
Bitcoin BTC$64,008▲ 1.5%
Ethereum ETH$1,791▲ 2.8%
Tether USDT$0.9994▲ 0.0%
BNB BNB$574.41▲ 1.0%
USDC USDC$0.9999▲ 0.0%
XRP XRP$1.1▲ 0.9%
Solana SOL$77.84▼ 0.1%
TRON TRX$0.33▼ 0.6%
Live data · CoinGecko · alternative.me (24h change)

Legal and Financial Impact of the Settlement

This settlement is significant because it provides a pathway for thousands of Americans to recover potentially substantial sums paid for prescription drugs over a decade. It highlights ongoing concerns over drug pricing and payment practices, and could influence future regulatory actions. For claimants, it offers a chance to recoup costs, potentially amounting to hundreds or thousands of dollars depending on individual circumstances.

Amazon

prescription drug reimbursement form

As an affiliate, we earn on qualifying purchases.

As an affiliate, we earn on qualifying purchases.

Background of the Prescription Payment Dispute

From 2009 to 2019, there have been ongoing debates and investigations into the pricing practices of pharmaceutical companies and the billing processes for prescription medications in the US. Previous lawsuits and regulatory inquiries have raised concerns about overcharges, improper billing, and lack of transparency. This settlement by Fine, Kaplan and Black, R.P.C., appears to be part of broader legal efforts to address these issues and provide restitution to affected consumers.

The announcement follows a series of legal actions and policy discussions aimed at increasing transparency and accountability in pharmaceutical billing practices.

“We are pleased to facilitate this settlement, which allows individuals who paid prescription costs during this period to seek reimbursement and hold accountable those responsible for overcharges.”

— Representative from Fine, Kaplan and Black, R.P.C.

Amazon

generic prescription medication organizer

As an affiliate, we earn on qualifying purchases.

As an affiliate, we earn on qualifying purchases.

Details of Eligibility and Claim Submission Still Unclear

While the settlement has been announced, specific eligibility criteria, claim submission procedures, and deadlines are still being finalized. It is not yet clear how many individuals are expected to participate or the total amount of funds available for reimbursement. Further details are expected to be released by the law firm or court overseeing the case.

Amazon

pill organizer for prescription drugs

As an affiliate, we earn on qualifying purchases.

As an affiliate, we earn on qualifying purchases.

Next Steps for Claimants and Settlement Process

Eligible individuals are advised to visit the official settlement website to review eligibility requirements and submit their claims. The claim submission window is expected to open shortly, with detailed instructions and deadlines to be announced. The law firm will likely provide updates on the total funds allocated and the timeline for processing claims.

Legal experts recommend claimants gather relevant documentation, such as receipts or payment records, to facilitate their submissions.

Amazon

prescription medication management kit

As an affiliate, we earn on qualifying purchases.

As an affiliate, we earn on qualifying purchases.

Key Questions

Who is eligible to file a claim in this settlement?

Individuals who paid for prescription drugs in the United States between May 1, 2009, and December 31, 2019, are eligible to participate, provided they meet specific criteria outlined on the settlement website.

How can I submit a claim?

Claimants should visit the official settlement website once the claims process opens, where they will find instructions, required documentation, and deadlines for submission.

Will I receive a specific amount of money?

The amount of reimbursement varies based on individual claims and the total funds available. Details will be provided after the claims are processed.

Does this settlement imply guilt on the part of pharmaceutical companies?

No, the settlement does not imply guilt or liability. It offers a resolution for affected consumers to recover overpaid costs.

When will the claims process close?

The deadline for submitting claims has not yet been announced. Claimants should monitor the official website for updates.

Source: primary

Nothing in this article is financial or investment advice. Cryptocurrency and precious-metal investments carry significant risk — do your own research and consider a licensed advisor.
NFL SEASON / TAI

NFL season / tailgating Picks

As an affiliate, we earn on qualifying purchases.

You May Also Like

Q32 Bio Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants

Q32 Bio plans to raise capital through a public offering of common stock and pre-funded warrants, details still pending, with implications for investors.

Ergebnisse Der Umfrage Zum Kreditgeschäft Im Euroraum Vom Juli 2026

Die Bundesbank hat die Ergebnisse ihrer Juli-Umfrage zum Kreditgeschäft im Euroraum veröffentlicht. Hier sind die wichtigsten Erkenntnisse und deren Bedeutung.

Cenovus To Hold Second-quarter 2026 Conference Call And Webcast On July 29

Cenovus will hold its second-quarter 2026 earnings conference call and webcast on July 29, providing updates to investors and analysts.

FINMA’s Supervision Of Small Banks: Proportionality As A Guiding Principle For Effective Supervision

FINMA highlights proportionality as a key principle in supervising small banks, aiming for more effective and tailored oversight practices.